Dr. Michael John Mauro, MD

Dr. Mauro practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Mauro's NPI, 1609884188, was assigned on August 3, 2006. Dr. Mauro graduated from Geisel School Of Medicine At Dartmouth in 1994. Dr. Mauro holds Oregon license MD22694.

Dr. Mauro's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Mauro's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Hematology Lymphoma Group. Dmand AI also links Dr. Mauro to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mauro practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Mauro's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dmand AI has Dr. Mauro's licenses on file in 8 states: Oregon, Florida, New York, New Jersey, New Hampshire, North Carolina, Maine and Oklahoma.

Dmand AI lists chronic leukemia, lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Mauro treats.

CMS data shows 597 Medicare services from Dr. Mauro across 3 procedure codes in 2024, for 207 Medicare patients. Medicare paid $71,121 for them.

CMS counts 207 Medicare patients who saw Dr. Mauro in 2024. The largest group is 65 to 74, with 103 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mauro's median patient age at 69, with 56% women.

In 2024, Dr. Mauro wrote 502 Medicare Part D claims for 92 patients. 39% of them were for generic drugs. CMS names the drug for 472 of them, across 10 drugs with 11 or more claims each, at $5,181,732 in total drug cost. In 2023, CMS named 664 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Mauro for performance year 2024, reported as part of a group. Dr. Mauro accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mauro as offering telehealth.

Dmand AI links 145 papers to Dr. Mauro, published from 2003 to 2025. 2017 was the busiest year, with 13. The most frequent topics are Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors and Antineoplastic Agents. Dr. Mauro has published most often in Leukemia. Dr. Mauro's most frequent co-authors are Jorge E. Cortes, MD, Brian Jay Druker, MD and Jerald P. Radich, MD.

Dmand AI links Dr. Mauro to 7 clinical trials, 2 of them phase 1 studies. Conditions studied include Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase and Myeloproliferative Disorders. Bristol-Myers Squibb sponsors the most, 2. Open Payments lists research payments to Dr. Mauro that name 2 trials.

CMS Open Payments shows 243 general payments to Dr. Mauro from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 58% of the total. Novartis Pharmaceuticals Corporation paid the most, $144,668. It also lists 40 research payments totaling $78,858 from 2016 to 2025, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Mauro, most recently CMS Stage 1 EHR in 2012.

Dr. Mauro graduated from Geisel School Of Medicine At Dartmouth in 1994.

Dr. Mauro is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.